TORONTO, April 17 (Reuters) - Canada's government health agency said on Tuesday it is working with the U.S. Food and Drug Administration to address a shortage of Mylan's MYL.O EpiPen allergy antidote that his hit several countries outside of the United States, where it is manufactured.
The efforts include "exploring access to international supply," a Health Canada spokeswoman told Reuters in an emailed statement.